• A$17.5 million placement completed to fund various initiatives
• Foundational U.S. patent granted until 2041
• New research collaborations in South America and Europe
• Cash position at 30 June 2026 was A$17.9 million
• Continued investor engagement in Asia-Pacific region

Blinklab Ltd, a digital healthcare company, has released its Quarterly Activities Report for Q4 FY26. Key highlights include the completion of a A$17.5 million placement to fund various initiatives such as FDA registrational studies, European regulatory activities, and ADHD program expansion. The company secured a foundational U.S. patent for its core technology, extending protection until 2041. New research collaborations were established with Ecuador's ESPOCH for autism and sensorimotor function studies and with Erasmus University Medical Center for evaluating treatment response to Activated PI3K Delta Syndrome. Blinklab's cash position at 30 June 2026 was approximately A$17.9 million. The company also engaged with global investors through events like the Ignite Investment Summits and Stocks in the Vines Investor Access Day.

Blinklab plans to complete its European ADHD study, continue its FDA 510(k) autism program, and prepare data for adult autism diagnostic and lifestyle monitoring studies. Results are expected in Q4 FY26.